• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    2/8/24 8:05:59 AM ET
    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELTX alert in real time by email

    Gainers

    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market cap stands at $2.2 million.
    • Titan Pharma (NASDAQ:TTNP) stock moved upwards by 27.59% to $8.0. The company's market cap stands at $6.0 million.
    • Trxade Health (NASDAQ:MEDS) shares rose 18.73% to $5.32. The company's market cap stands at $6.4 million.
    • Elicio Therapeutics (NASDAQ:ELTX) shares moved upwards by 17.8% to $3.97. The company's market cap stands at $38.1 million.
    • Nutex Health (NASDAQ:NUTX) stock increased by 17.63% to $0.13. The market value of their outstanding shares is at $97.9 million.
    • Mineralys Therapeutics (NASDAQ:MLYS) shares rose 16.51% to $14.53. The market value of their outstanding shares is at $597.2 million.

    Losers

    • Jin Medical International (NASDAQ:ZJYL) shares decreased by 93.9% to $13.26 during Thursday's pre-market session. The market value of their outstanding shares is at $103.7 million.
    • Tenax Therapeutics (NASDAQ:TENX) shares fell 52.39% to $6.79. The company's market cap stands at $2.3 million.
    • InVivo Therapeutics Hldg (NASDAQ:NVIV) stock declined by 17.61% to $0.53. The company's market cap stands at $1.6 million.
    • HOOKIPA Pharma (NASDAQ:HOOK) shares declined by 13.6% to $0.58. The market value of their outstanding shares is at $57.6 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares fell 13.1% to $0.73. The company's market cap stands at $2.2 million.
    • Exicure (NASDAQ:XCUR) stock declined by 13.02% to $0.59. The company's market cap stands at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ELTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELTX
    $HOOK
    $MEDS
    $MLYS

    CompanyDatePrice TargetRatingAnalyst
    Mineralys Therapeutics Inc.
    $MLYS
    6/11/2025$15.00Hold
    Jefferies
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    Tenax Therapeutics Inc.
    $TENX
    10/24/2024$16.00Outperform
    Leerink Partners
    Tenax Therapeutics Inc.
    $TENX
    10/14/2024$16.00Buy
    Guggenheim
    Tenax Therapeutics Inc.
    $TENX
    9/30/2024Outperform
    William Blair
    Nutex Health Inc.
    $NUTX
    9/18/2024$45.00Buy
    Maxim Group
    More analyst ratings

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      4/25/25 7:01:59 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      3/26/25 5:41:19 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

      NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series C Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 60,000 shares of Preferred Stock for an aggregate purchase price of $600,000. The shares have a conversion price of $3.40. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "blocke

      6/27/25 4:05:00 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exicure, Inc. Reports First Quarter 2025 Financial Results

      Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("G

      6/27/25 4:01:00 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NUTEX HEALTH ANNOUNCES THAT IT HAS FILED A SUPPLEMENT TO ITS PROXY STATEMENT

      HOUSTON, June 27, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced that it has filed a supplement to the proxy statement it filed on June 2, 2025. The Company encourages shareholders to review the supplement filed today. As a reminder, the Company's Annual Meeting of common stockholders will be held on July 14, 2025 at 10:00 am Central Time. Stockholders may view our definitive proxy statement dated June 2, 2025 and our

      6/27/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Mineralys Therapeutics with a new price target

      Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

      6/11/25 7:54:20 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

      12/20/24 7:37:05 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

      RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

      11/15/24 11:07:50 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Rodman David Malcom exercised 6,348 shares at a strike of $1.08 and sold $165,931 worth of shares (11,366 units at $14.60), decreasing direct ownership by 5% to 101,651 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      6/16/25 4:03:20 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chudnovsky Yekaterina

      4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

      6/4/25 5:08:28 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 2% to 325 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      5/23/25 6:19:40 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Exicure Inc.

      10-Q - EXICURE, INC. (0001698530) (Filer)

      6/27/25 4:43:47 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exicure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EXICURE, INC. (0001698530) (Filer)

      6/27/25 4:29:56 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Titan Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      6/27/25 4:15:19 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELTX
    $HOOK
    $MEDS
    $MLYS
    Financials

    Live finance-specific insights

    See more
    • Exicure, Inc. Reports First Quarter 2025 Financial Results

      Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("G

      6/27/25 4:01:00 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

      – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p<0.0001) – – Lorundrostat demonstrated a favorable safety and tolerability profile – – Conference call today at 8:00 a.m. ET – RADNOR, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep

      6/17/25 7:00:00 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for

      5/12/25 4:05:00 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care